CelLBxHealth plc

 ("CelLBxHealth" or "the Company")

Collaboration with AdventHealth for two studies monitoring CTCs to improve cancer care

·    AdventHealth, one of the largest faith-based health systems in the United States

·    CTC analysis will be an endpoint in two multi-centre studies in colon, gastrointestinal and lung cancer

Guildford, UK and Plymouth Meeting, U.S. - 18 May 2026 - CelLBxHealth plc (AIM:CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces a collaboration with AdventHealth, one of the largest faith-based health systems in the United States, for the use of CelLBxHealth's Parsortix® platform in two  clinical studies. The studies, titled ACTION and SUNRISE, will employ minimally invasive cancer monitoring by isolating and analysing circulating tumour cells (CTCs) from patients undergoing treatment.

These studies mark an important advance in the use of minimally invasive diagnostics to better understand treatment response, improve outcomes, and expand access to precision oncology in community settings. Using the Parsortix platform, researchers will isolate and analyse CTCs from blood samples, enabling both enumeration and PD-L1 characterisation to provide real-time insight into tumour biology without the need for invasive biopsies.

The ACTION study (Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer) is a multi-site, NIH-funded trial currently enrolling 219 patients to evaluate how different doses of aerobic exercise influence chemotherapy tolerability in colon cancer patients (NCT05773144). The SUNRISE study (Statewide Unified Network for Remote Intervention of Strength and Exercise) is a digitally enabled trial in 120 patients with gastrointestinal and lung cancers, assessing whether remotely delivered exercise interventions can improve chemotherapy tolerance and quality of life expected to commence in July 2026. Across both studies, CTC analysis will serve as a novel correlative endpoint, helping researchers understand how the tumour evolves in response to treatment and behavioural interventions.

A central aim of both studies is to enable more patient-centric care by bringing advanced cancer monitoring closer to patients' homes. With most cancer patients in the United States treated in the community, the combination of remote interventions and simple blood-based diagnostics has the potential to reduce patient burden, minimise travel, and support continuous monitoring regardless of location. This approach also addresses persistent health inequalities that limit access to specialised cancer care, particularly for underserved populations.

AdventHealth's extensive national network of hospitals and outpatient facilities provides a powerful platform to scale these innovations in real-world clinical practice. For CelLBxHealth, the collaboration represents a significant commercial opportunity to validate and expand adoption of the Parsortix platform across a large, integrated healthcare system, supporting broader use of liquid biopsy in routine oncology care.

Peter Collins, CEO of CelLBxHealth, commented: "This collaboration with AdventHealth demonstrates the growing importance of accessible, non-invasive technologies in modern oncology. By enabling detailed analysis of CTCs through a simple blood draw, we are helping to bring precision medicine into the community and closer to patients who need it most."

Justin Brown, PhD, Principal Investigator and Director of the Exercise and Cancer Biology Research Program at AdventHealth, added: "These studies allow us to pair advanced technology with a whole-person approach to cancer care. By combining exercise interventions with advanced biomarkers like CTCs, we aim to improve treatment tolerance, better understand how tumours respond to therapy and provide care that is more accessible for patients across diverse communities."

As the ACTION and SUNRISE studies progress, CelLBxHealth and AdventHealth aim to further establish the clinical utility of CTC analysis in guiding treatment decisions and improving cancer care delivery. Together, the organisations are working to redefine how cancer is monitored and treated, advancing a more equitable and patient-centred model of care.

For further information:

Notes for editors 

About AdventHealth

AdventHealth is a connected network of care that helps people feel whole - body, mind and spirit. More than 100,000 team members across a national footprint provide whole-person care to nearly nine million people annually through more than 2,000 care sites that include hospitals, physician practices, ambulatory surgery centres, outpatient clinics, home health agencies, hospice centres, the AdventHealth app and more. Our wholistic approach to improving the health and prosperity of our communities is inspired by our mission to extend the healing ministry of Christ.

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial focus span three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.

For more information, visit https://cellbxhealth.com/.